Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).-MedSci.cn

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

Wang, J; Yu, XM; Lu, S; Hu, YP; Sun, YP; Wang, ZJ; Zhao, J; Yu, Y; Hu, CH; Yang, KY; Feng, GS; Ying, KJ; Zhuang, W; Zhou, JY; Wu, JX; Wu, YJ; Lin, X; Liang, L; Yang, N

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

科室

工具

服务